Private Capital Research LLC (“PCR”) is a unique investment and consulting organization that provides high quality investment opportunities for private capital investors in the lower end of the middle market. PCR works only on the buy-side for a select number of private equity investors and corporate clients to source and originate investment opportunities that fit their criteria on both a generalist, opportunistic basis and a specific search basis. PCR sources opportunities to acquire, or invest in, companies that have between $10 and $500 million in revenues.

PCR was formed to meet the needs of middle market private equity investors that would like to see additional high-quality deal flow, and corporate clients that are executing acquisition strategies to grow their businesses. Opportunities are sourced directly, as well as from a network of advisors, key professionals, and influential individuals who may be retained on the sell-side to create liquidity (or take advantage of growth opportunities) for owners of companies at a crossroads in their overall development.

PCR’s clients are private equity investment funds, family backed buyout groups or corporations that are not generally well known to PCR’s advisor network. PCR provides outsourced business development services to source and originate deal opportunities that fit our clients’ investment criteria, and PCR invests in deals with clients.

Current retained engagements range from committed private equity funds with $130 to over $300 million in their current investment vehicles, to family-backed investment firms with capital in the billions. Please click here for detailed investment criteria for each of our clients.

On this web site, you can learn more about how we work with our clients to develop acquisition strategies and how we implement and execute these strategies. You will also find detailed information on our current acquisition criteria and parameters as well as background information on the firm’s principals.